Skip to main content

Coronary Restenosis clinical trials at University of California Health

1 research study open to eligible people

Showing trials for
  • SELUTION SLR™ 014 In-stent Restenosis

    open to eligible people ages 18 years and up

    Prospective, multi-center, randomized, single blind, controlled, noninferiority clinical trial. Subjects with previous bare-metal stent (BMS) or DES and qualifying evidence for ISR will be screened per the protocol inclusion and exclusion criteria. Eligible subjects will be randomized 1:1 to treatment with either the SELUTION SLR™ 014 DEB or SOC to include contemporary DES (zotarolimus-eluting stents [ZES] and everolimus-eluting stents [EES] only) or BA. A maximum of 20% of patients randomized to SOC will be treated with BA. The primary endpoint will be Target Lesion Failure (TLF) at 12-months in the SOC group vs. the SELUTION SLR™ 014 DEB in all patients.

    at UCLA

Our lead scientists for Coronary Restenosis research studies include .

Last updated: